Heidelberg, Germany, October 30, 2017 - Affimed N.V. AFMD, a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on November 7, 2017, the Company will release its financial results for the quarter ended September 30, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, November 7, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3213767.
Local - Amsterdam, the Netherlands: +31 (0)20 716 8295
Local - Copenhagen, Denmark: +45 32 71 16 60
Local - Frankfurt, Germany: +49 (0)69 2222 10625
Local - Zurich, Switzerland: +41 (0)44 580 7214
Local - London, U.K.: +44 (0)20 3427 1907
Local - New York City, U.S.A.: +1 646 254 3366
Local - Paris, France: +33 (0)1 76 77 22 23
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed AFMD engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: a.alexandru@affimed.com, IR@affimed.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
